~~<i id='ECE95D76C3'><strike id='ECE95D76C3'><tt id='ECE95D76C3'><pre id='ECE95D76C3'></pre></tt></strike></i>~~

Home» leisure time» knowledge

knowledge

author：leisure time 2025-09-30 05:50:39 Page View：41

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Mike Pence ‘not interested in trading insults’ with Trump as he tries to win New Hampshire
Next article： ChatGPT in medicine: STAT answers readers' burning questions

explore

Peter Hotez and the public health issue of online harassment

AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

What Henrietta Lacks's story taught me about my role as a doctor

MikeReddyforSTATWhenIwasinmedicalschool,duringmyOB-GYNrotation,oneofmyclassmatessaidtome,“Somepeople

Virginia high school admissions case could be legal follow

3:24DemonstratorsprotestoutsideoftheSupremeCourtinWashington,Thursday,June29,2023,aftertheSupremeCou

Is there really a nursing shortage in the U.S.?

StrikingKaiserPermanenteworkersinCaliforniaholdsignsastheymarchinfrontoftheKaiserPermanenteSanFranci